Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia

Leukemia and Lymphoma

Volumn 36, Issue 5-6, 2000, Pages 479-484

  Cortes, Jorge ^a,b   Estey, Elihu ^a   Beran, Miloslav ^a   O'Brien, Susan ^a   Giles, Francis ^a   Koller, Charles ^a   Keating, Michael ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute leukemia; Cyclophosphamide; Cytarabine; Salvage; Topotecan

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; FLUCONAZOLE; ITRACONAZOLE; QUINOLONE; SULFAMETHOXAZOLE; TOPOTECAN; TRIMETHOPRIM;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DIARRHEA; DNA DAMAGE; FLUSHING; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HUMAN CELL; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RELAPSE; SEPSIS; SIDE EFFECT; VOMITING;

EID: 0033963520     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009148395     Document Type: Article

References (32)

1. Rowe, J.M. & Liesveld, J.L. (1996). Treatment and prognostic factors in acute myeloid leukemia. Baillieres Clinical Hematology, 9, 87-105.
2. Estey, E.H. (1995). Treatment of acute myelogenous leukemia and myelodysplastic syndromes. Seminars in Hematology, 32, 132-151.
3. Liu, L.F. (1989). DNA topoisomerase poisons as antitumor drugs. Annual Review of Biochemistry, 58, 351-375.
4. Nagata, H., Kaneda, N., Furuta, T., Sawada, S., Yokokura, T., Miyasaka, T., Fukada, M. & Notake, K. (1987). Action of 7-ethylcamptothecin on tumor cells and its disposition in mice. Cancer Treat Rep, 71, 341-348.
5. Giovanella, B.C., Stehlin, J.S., Wall, M.E., Wani, M.C., Nicholas, A.W., Liu, L.F., Silber, R. & Potmesil, M. (1989). DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science, 246, 1046-1048.
6. Saltz, L., Sirott, M., Young, C., Tong, W., Niedzwiecki, D., Tzy-Jyun, Y., Tao, Y., Trochanowski, B., Wright, P., Barbosa, K. & et al. (1993). Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor [published erratum appears in J Natl Cancer Inst 1993 Nov 3;85(21):1777]. Journal of the National Cancer Institute, 85, 1499-1507.
7. Rowinsky, E.K., Grochow, L.B., Hendricks, C.B., Ettinger, D.S., Forastiere, A.A., Hurowitz, L.A., McGuire, W.P., Sartorius, S.E., Lubejko, B.G., Kaufmann, S.H. & et al. (1992). Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. Journal of Clinical Oncology, 10, 647-656.
8. Rowinsky, E.K., Adjei, A., Donehower, R.C., Gore, S.D., Jones, R.J., Burke, P.J., Cheng, Y.C., Grochow, L.B. & Kaufmann, S.H. (1994). Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. Journal of Clinical Oncology, 12, 2193-2203.
9. Kantarjian, H.M., Beran, M., Ellis, A., Zwelling, L., O'Brien, S., Cazenave, L., Koller, C., Rios, M.B., Plunkett, W., Keating, M.J. & et al. (1993). Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood, 81, 1146-1151.
10. Rowinsky, E.K. & Kaufmann, S.H. (1997). Topotecan in combination chemotherapy. Seminars in Oncology, 24, S20-11-S20-26.
11. Beran, M., Estey, E.H., O'Brien, S., Cortes, J., Koller, C.A., Giles, F.J., Kornblau, S., Andreeff, M., Vey, N., Pierce, S.R., Hayes, K., Wong, G.C., Keating, M. & Kantarjian, H. (1999). Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. Journal of Clinical Oncology, In press.
12. Seiter, K., Feldman, E.J., Halicka, H.D., Traganos, F., Darzynkiewicz, Z., Lake, D. & Ahmed, T. (1997). Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. Journal of Clinical Oncology, 15, 44-51.
13. Boothman, D.A., Wang, M., Schea, R.A., Burrows, H.L., Strickfaden, S. & Owens, J.K. (1992). Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells. International Journal of Radiation Oncology, Biology, Physics, 24, 939-948.
14. Kano, Y., Suzuki, K., Akutsu, M., Suda, K., Inoue, Y., Yoshida, M., Sakamoto, S. & Miura, Y. (1992). Effects of CPT-11 in combination with other anti-cancer agents in culture. International Journal of Cancer, 50, 604-610.
15. Giovanella, B., Potmesil, M. & Wall, M.E. (1994). Treatment of human cancer xenografts with camptothecin analog in combination with cytoxan or x-irradiation. Proc Am Assoc Cancer Res, 35, 454 (Abstract #2711).
16. Nitiss, J.L., Rose, A.M. & Sykes, K.C. (1996). DNA topoisomerase I sensitizes cells to DNA damage. Proc Am Assoc Cancer Res, 37, 428)Abstract #2923).
17. Mattern, M.R., Hofmann, G.A., McCabe, F.L. & Johnson, R.K. (1991). Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Research, 51, 5813-5816.
18. Musk, S.R. & Steel, G.G. (1990). The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase. British Journal of Cancer, 62, 364-367.
19. Murren, J.R., Anderson, S., Fedele, J., Pizzorno, G., Belliveau, D., Zelterman, D., Burtness, B.A., Tocino, I., Flynn, S.D., Beidler, D. & Cheng, Y.C. (1997). Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. Journal of Clinical Oncology, 15, 148-157.
20. Saylors, R.L., 3rd, Stewart, C.F., Zamboni, W.C., Wall, D.A., Bell, B., Stine, K.C. & Vietti, T.J. (1998). Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study. Journal of Clinical Oncology, 16, 945-952.
21. Cheson, B.D., Cassileth, P.A., Head, D.R., Schiffer, C.A., Bennett, J.M., Bloomfield, C.D., Brunning, R., Gale, R.P., Grever, M.R., Keating, M.J. & et al. (1990). Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol, 8, 813-819.
22. Estey, E. (1996). Treatment of refractory AML. Leukemia, 10, 932-936.
23. Estey, E., Kornblau, S., Pierce, S., Kantarjian, H., Beran, M. & Keating, M. (1996). A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia [letter]. Blood, 88, 756.
24. Kantarjian, H.M., Estey, E.H. & Keating, M.A. (1996). New chemotherapeutic agents in acute myeloid leukemia. Leukemia, 10 Suppl 1, S4-6.
25. Beran, M., Estey, E., O'Brien, S.M., Giles, F.J., Koller, C.A., Kornblau, S., Keating, M. & Kantarjian, H.M. (1998). Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia [In Process Citation]. Leuk Lymphoma, 31, 521-531.
26. Beran, M., Kantarjian, H., O'Brien, S., Koller, C., al-Bitar, M., Arbuck, S., Pierce, S., Moore, M., Abbruzzese, J.L., Andreeff, M., Keating, M. & Estey, E. (1996). Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 88, 2473-2479.
27. Hoogstraten, B. (1960). Cyclophosphamide (Cytoxan) in acute leukemia, preliminary report. Cancer Chemother Rep, 8, 116-119.
28. Pierce, M., Shore, N., Sitarz, A., Murphy, M.L., Louis, J. & Severo, N. (1966). Cyclophosphamide therapy in acute leukemia of childhood. Cooperative study conducted by members of Children's Cancer Cooperative Group A. Cancer, 19, 1551-1560.
29. Freedman, M.H., Finklestein, J.Z., Gilchrist, G.S., Hammond, G.D., Higgins, G.R., Hyman, C.B., Shore, N.A., Williams, K.O & Karon, M.R. (1969). Preliminary evaluation of Cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in acute leukemia of children. Cancer Chemotherapy Reports - Part 1, 53, 299-303.
30. Ansari, B.M. & Thompson, E.N. (1973). Refractory leukemia treated with cytosine arabinoside and cyclophosphamide. Cancer, 32, 294-297.
31. Bodey, G.P., Rodriguez, V., Hart, J. & Freireich, E.J. (1970). Therapy of acute leukemia with the combination of cytosine arabinoside (NSC-63878) and cyclophosphamide (NSC-26271). Cancer Chemotherapy Reports - Part 1, 54, 255-262.
32. Uckun, F.M., Stewart, C.F., Reaman, G., Chelstrom, L.M., Jin, J., Chandan-Langlie, M., Waddick, K.G., White, J. & Evans, W.E. (1995). In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. Blood, 85, 2817-2828.